Research
Hormonal
Obesity increases the risk and severity of periodontitis through systemic inflammation and adipokine release, creating a bidirectional relationship where higher BMI correlates with poorer periodontal outcomes.
Higher body weight is biologically linked to more severe gum disease due to inflammation. If you are overweight, you are at higher risk for gum bone loss. Managing weight and treating gum disease are interconnected parts of your overall health.
GoodSupportsHIGH confidence
Obesity is associated with increased risk for onset of periodontitis, increased severity of disease in those with periodontitis and poorer outcomes following periodontal treatment.
Why this rating
Supported by large body of epidemiological, cross-sectional, and longitudinal studies.
Source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Crystal Marruganti et al. · Periodontology 2000 · 2023
DOI 10.1111/prd.12536
narrative_reviewCited 76×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Subgingival instrumentation (periodontal therapy) significantly reduces glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, demonstrating a bidirectional benefit where treating periodontitis improves metabolic control.Good
- Combined adherence to healthy lifestyle factors (Mediterranean diet, physical activity, non-smoking, moderate alcohol, ideal weight) significantly reduces the risk of developing periodontitis and tooth loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →